2022
DOI: 10.3390/biomedicines10020372
|View full text |Cite
|
Sign up to set email alerts
|

A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences

Abstract: Giant cell tumor of bone (GCTB) and desmoplastic fibroma (DF) are bone sarcomas with intermediate malignant behavior and unpredictable prognosis. These locally aggressive neoplasms exhibit a predilection for the long bone or mandible of young adults, causing a severe bone resorption. In particular, the tumor stromal cells of these lesions are responsible for the recruiting of multinucleated giant cells which ultimately lead to bone disruption. In this regard, the underlying pathological mechanism of osteoclast… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
21
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 34 publications
(27 citation statements)
references
References 47 publications
1
21
0
Order By: Relevance
“…Antibody-drug conjugate (ADC) drugs against NY-ESO-1 have already demonstrated evidence of activity. 38 Additionally, some new biomarkers such as neurotrophic tyrosine receptor kinase (NTRK), 11 RANK-L, 12 and corresponding drugs larotrectinib, denosumab have also been shown to affect certain sarcomas dramatically.…”
Section: Discussionmentioning
confidence: 99%
“…Antibody-drug conjugate (ADC) drugs against NY-ESO-1 have already demonstrated evidence of activity. 38 Additionally, some new biomarkers such as neurotrophic tyrosine receptor kinase (NTRK), 11 RANK-L, 12 and corresponding drugs larotrectinib, denosumab have also been shown to affect certain sarcomas dramatically.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, literature data suggest that genes involved in bone vascular formation, such as OPG and VEGF seem to have a potential role as new antiangiogenic generation drugs, including the multitarget tyrosine-kinase inhibitor lenvatinib. Interestingly, the combination of denosumab and lenvatinib seems to be a promising therapeutic strategy in GCTB [ 20 , 21 ].…”
Section: Discussionmentioning
confidence: 99%
“…In particular, the axis RANK/RANKL/OPG was significantly unbalanced towards the bone resorption activation, which is responsible for orchestrating the bone vicious cycle and the activation of osteoclastogenesis potential. Furthermore, in vitro and in vivo zebrafish analyses provided evidence for suggesting the combination of denosumab and multitarget TKI inhibitor lenvatinib as a promising therapeutic strategy in GCTB and DF compared to monoregimen chemotherapy ( 29 ). This report provided useful methods and ideas for the study of the molecular mechanism and potential therapeutic targets in adamantinoma.…”
Section: Discussionmentioning
confidence: 99%